CSL Limited is a global biotechnology company listed on the Australian Securities Exchange, headquartered in Parkville, Victoria. Incorporated 1916 as Commonwealth Serum Laboratories (Commonwealth of Australia), privatised 1994, and now operating three principal divisions — CSL Behring (plasma-derived and recombinant therapies), CSL Seqirus (influenza vaccines, second-largest globally), and CSL Vifor (iron deficiency, nephrology; acquired 2022 for approx. US$11.7B).
Global workforce approx. 32,000. Manufacturing sites in Australia, United States, Switzerland, Germany, United Kingdom, and China. Plasma collection network of ≥330 centres concentrated in the United States.
| Area | Active Trials | Patents (24m) | Lead Candidate | Status |
|---|---|---|---|---|
| Immunoglobulins · PID/SID | 34 | 218 | Privigen / Hizentra LC | MARKETED |
| Haemophilia | 18 | 164 | Hemgenix (AAV-FIX) | MARKETED |
| Hereditary Angioedema | 9 | 41 | Garadacimab (CSL312) | PHASE 3 |
| Influenza Vaccines | 22 | 108 | Flucelvax · Fluad | MARKETED |
| Iron Deficiency · CKD | 15 | 37 | Ferinject (ferric carboxymaltose) | MARKETED |